long-term side effects of glp-1 medications long term Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus Comparing GLP‑1 Drugs With Other – Is GLP-1 the Same as

As healthcare systems grapple with the burdens of these conditions, the availability of effective pharmacotherapy can alleviate some of the strain on medical resources

In clinical trials, discontinuation of Tesamorelin resulted in a return of visceral fat toward baseline levels over 36 months, suggesting ongoing use may be needed to maintain body composition benefits

A significant reduction in pro-inflammatory molecules, including C-reactive protein (CRP), TNF- , and IL-6, was observed, indicating the inhibition of inflammatory pathways, likely at the level of immune system cells and adipocytes signaling

By 20082009, phase 3 trials (collectively named the LEAD trials Liraglutide Effect and Action in Diabetes) were completed

Study: GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea

Topiramate inhibits trigeminovascular activation: An intravital microscopy study